Cinven is reviewing strategic options for laboratory-services company Synlab International GmbH including a potential sale, people with knowledge of the matter said.
The private equity firm has been speaking with potential advisers and could start a sale process early next year, the people said, asking not to be identified because the information is private. Cinven plans to seek a valuation of about 5.5 billion euros ($6 billion) including debt for Augsburg, Germany-based Synlab, one of the people said.
A sale of Synlab would likely attract other private equity firms, the people said. No final decision has been made, and Cinven could elect to keep the business, the people said. A spokeswoman for Cinven declined to comment, while Synlab didn’t answer phone calls seeking comment.
Cinven first invested in Synlab in June 2015, buying a majority stake from fellow private equity firm BC Partners for about 1.7 billion euros, Bloomberg News reported at the time. It combined the business with Labco SA, which it agreed to buy earlier that year for 1.2 billion euros.
Synlab, led by Chief Executive Officer Mathieu Floreani, also counts Novo A/S and Ontario Teachers’ Pension Plan as minority investors, according to its website. It operates across more than 40 countries, handling more than 500 million clinical tests annually, according to Synlab’s website.
Cinven also owns stakes in retailer Kurt Geiger and German drugmaker Stada Arzneimittel AG, according to its website.
The sale plan comes at a time when Cinven’s rival Apax Partners is also weighing a sale of diagnostic services business Unilabs. The buyout firm is working with advisers at Rothschild & Co. to look at options for the business, people familiar with the matter said last week.
Source: Bloomberg
Can’t stop reading? Read more
J.P. Morgan Asset Management launches first Eltif for private market exposure
J.P. Morgan Asset Management (JPMAM) introduced its first European Long-Term Investment Fund (Eltif). The fund provides investors with globally diversified access to private markets through a single, actively managed fund. Eltifs, regulated under the EU framework, are...
Morphosis Capital launches €100m Fund II to boost SME growth in Romania
Morphosis Capital launched its second fund, Morphosis Capital Fund II, securing over €100m in committed capital—double the size of its predecessor. The Romania-based private equity firm aims to invest in SMEs across Romania and neighbouring regions, targeting sectors...
Update: MidEuropa secures €1bn exit as Diagnostyka debuts on Warsaw Stock Exchange
MidEuropa-backed Diagnostyka, a leading Polish diagnostic service provider, made its stock market debut on 7 February 2025, achieving a valuation of over €1bn. The IPO stands among the largest private equity-backed public exits in recent years. Priced at PLN105 (€25)...